Aytu Biopharma, Inc. AYTU
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 99.92% | -240.66% | -1,443.15% | 33.31% | -329.24% |
| Total Depreciation and Amortization | -23.43% | -12.90% | -31.50% | -39.81% | -6.03% |
| Total Amortization of Deferred Charges | 7.69% | 0.00% | 3.57% | 7.41% | -80.60% |
| Total Other Non-Cash Items | -102.14% | 231.46% | 480.41% | -4.98% | 443.59% |
| Change in Net Operating Assets | 116.56% | 82.15% | 22.25% | 97.10% | 218.51% |
| Cash from Operations | 57.19% | 35.21% | 26.51% | 48.07% | 455.71% |
| Capital Expenditure | 29.41% | 100.00% | -183.33% | -- | 94.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -1,116.95% |
| Cash from Investing | 99.60% | 100.00% | -111.72% | -- | -8,773.53% |
| Total Debt Issued | -251.12% | -77.79% | -2,147.29% | 209.87% | -93.54% |
| Total Debt Repaid | -644.18% | 0.00% | 0.00% | 0.00% | 97.04% |
| Issuance of Common Stock | -- | -- | -- | -- | 338.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 100.00% | 100.00% | -510.00% | -378.95% |
| Cash from Financing | -136.95% | -79.72% | -126.92% | 152.03% | 1,116.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -103.18% | -48.76% | -998.28% | 1,545.10% | 5,094.72% |